Currently, an ongoing phase 1 trial is underway to evaluate the safety and efficacy of a novel IDH1 inhibitor (LY3410738) in advanced solid tumors with IDH1 mutations, including melanomas (NCT04521686). Here, IDH1 is linked to melanoma.